SEC 13F Intelligence

Gw Henssler & Associates Ltd / REGN

Gw Henssler & Associates Ltd’s Regeneron Pharmaceuticals Position

Does Gw Henssler & Associates Ltd own Regeneron Pharmaceuticals (REGN)? Yes — 23.9K shares worth $18M (+0.87% of its 13F portfolio) as of Q1 2026, down from 24.4K shares the prior filed quarter.

Position Value
$18M
Q1 2026
Shares
23.9K
% of Portfolio
+0.87%
Quarters Held
27
currently held

Position History REGN

Reported value by quarter
Q2 ’19: $9MQ2 ’19Q3 ’19: $10MQ4 ’19: $14MQ1 ’20: $18MQ2 ’20: $21MQ2 ’20Q3 ’20: $11MQ4 ’20: $9MQ1 ’21: $9MQ2 ’21: $11MQ2 ’21Q3 ’21: $12MQ4 ’21: $13MQ1 ’22: $14MQ2 ’22: $12MQ2 ’22Q3 ’22: $14MQ4 ’22: $15MQ1 ’23: $17MQ2 ’23: $15MQ2 ’23Q3 ’23: $17MQ4 ’23: $18MQ1 ’24: $19MQ2 ’24: $19MQ2 ’24Q3 ’24: $19MQ4 ’24: $19MQ1 ’25: $13MQ2 ’25: $11MQ2 ’25Q4 ’25: $19MQ1 ’26: $18Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q1 202623.9K$18M+0.87%
Q4 202524.4K$19M+0.91%
Q2 202521.5K$11M+0.60%
Q1 202520.4K$13M+0.74%
Q4 202417.8K$19M+1.07%
Q3 202418.1K$19M+1.07%
Q2 202418.5K$19M+1.17%
Q1 202419.5K$19M+1.10%
Q4 202320.0K$18M+1.16%
Q3 202320.5K$17M+1.15%
Q2 202320.9K$15M+0.99%
Q1 202321.1K$17M+1.15%
Q4 202221.3K$15M+1.08%
Q3 202220.9K$14M+1.08%
Q2 202220.5K$12M+0.90%
Q1 202220.4K$14M+0.87%
Q4 202120.0K$13M+0.81%
Q3 202119.9K$12M+0.84%
Q2 202119.9K$11M+0.73%
Q1 202119.4K$9M+0.66%
Q4 202018.5K$9M+0.68%
Q3 202020.3K$11M+0.96%
Q2 202034.0K$21M+1.87%
Q1 202036.9K$18M+1.83%
Q4 201938.0K$14M+1.18%
Q3 201936.1K$10M+0.89%
Q2 201927.7K$9M+0.79%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Gw Henssler & Associates Ltd’s full portfolio or all institutional holders of REGN.